Cargando…
Safety and efficacy of Siddha management as adjuvant care for COVID-19 patients admitted in a tertiary care hospital - An open-label, proof-of-concept Randomized Controlled Trial
BACKGROUND: COVID-19 resulted in loss of human lives owing to respiratory failure caused by dysregulated immune system. Though many treatments are evaluated, the most appropriate is yet to be established. OBJECTIVE: To determine the safety and efficacy of Siddha add-on therapy in COVID -19 in terms...
Autores principales: | Christian, Gnanaraj Johnson, Meenakumari, Ramasamy, Shanthimalar, Ramalingam, Sankar, Ganesan, Ravichandran, Vadugam Muthusamy, Elansekaran, Selladurai, Ramamurthy, Murugan, Srinivasan, Venkatachalam, Rajalakshmi, Elumalai, Boopathi, Kangusamy, Vennila, Kesavan, Nijavizhi, Mohanasundaram, Shakthi Paargavi, Ambalavanan, Aruldevi, Selvam, Priyanka, Sekaran, Gajalakshmi, Govindasamy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086104/ https://www.ncbi.nlm.nih.gov/pubmed/37197717 http://dx.doi.org/10.1016/j.jaim.2023.100706 |
Ejemplares similares
-
Clinical outcomes among COVID-19 patients managed with modern and traditional Siddha medicine – A retrospective cohort study
por: Meenakumari, Ramaswamy, et al.
Publicado: (2022) -
STANDARDISATION OF SIDDHA DRUGS
por: Saraswathy, Ariamuthu
Publicado: (1994) -
Efficacy of Siddha Therapeutics on Mantha Sanni (Autism Spectrum Disorder) Among Pediatric Patients: An Interventional Non-randomized Open-Label Clinical Trial
por: Elangovan, Preetheekha, et al.
Publicado: (2023) -
ON THE ANTIBACTERIAL ACTIVITY OF SOME SIDDHA MEDICINES
por: Alam, Muzaffer, et al.
Publicado: (1998) -
Siddha management of alcohol withdrawal syndrome
por: Selvasankari, E, et al.
Publicado: (2022)